Skip to content

A Comparison of SmartPill Capsule With Scintigraphy for Determining Gastric Residence Time - Over 65 Years Old

A Comparison Trial of SmartPill Corporation GI Monitoring System With Scintigraphic Gastric Emptying Procedure for Determining Gastric Residence Time - In Subjects Over 65 Years of Age

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00682877
Acronym
GETOver65
Enrollment
23
Registered
2008-05-23
Start date
2007-07-31
Completion date
2007-11-30
Last updated
2008-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Diseases, Gastroparesis, Stomach Diseases

Keywords

gastroparesis, Digestive, Gastrointestinal, Stomach, Motility, Non-Invasive, Capsule, GI, Device, Digestive System Diseases

Brief summary

The purpose of this study is to determine the correlation between gastric residence time of the SmartPill Capsule and the time required for partial emptying of a standard radiolabeled meal as measured by gastric emptying scintigraphy for subjects 65 years of age and older.

Detailed description

Gastric emptying scintigraphy is considered the gold standard for evaluating gastric emptying and is widely available. Accurate characterization of gastric emptying may guide medical and surgical treatment choices. In addition, these techniques may allow for monitoring of therapeutic results for follow-up patient management. The SmartPill GI Monitoring System offers an alternative non-invasive method for characterizing disorders of the stomach. The system consists of an ingestible capsule that houses sensors for pH, temperature, and pressure, a receiver for receiving and storing signals from the capsule, and software for displaying data on a personal computer. The capsule samples at regular intervals and transmits the sensed pH, pressure, and temperature data to a portable receiver worn by the subject. After test completion, the recorded data is downloaded to a personal computer for subsequent evaluation. This trial is for subjects 65 years of age and older.

Interventions

None listed

Sponsors

The SmartPill Corporation
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Inclusion Criteria For Healthy Subjects: * Healthy males and females between ages 65-80 years of age with no gastrointestinal disease as screened by the GI Disease Screening Questionnaire * Average bowel movement frequency of at least one bowel movement within 48 hours * Subjects with high probability for compliance and completion of the study * Inclusion Criteria For Subjects with Gastroparesis: * Abnormal gastric emptying as defined by local standards and documented by nuclear medicine scintigraphy performed within the last two years. * Males and females between ages 18-65 years of age. * Average bowel movement frequency of at least one bowel movement within 72 hours * Subjects with high probability for compliance and completion of the study * Upper endoscopy or upper GI within last 3 years showing no evidence of gastric bezoar, stricture, or peptic ulcer.

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frame
To demonstrate the correlation between the gastric residence time as determined by SmartPill GI Monitoring System and the gastric emptying time of a radiolabeled meal in both healthy subjects and patients with documented gastroparesis.30 minute intervals up to 6 hours

Secondary

MeasureTime frame
To demonstrate that the gastric residence time as determined by SmartPill GI Monitoring System can discriminate between healthy human subjects and patients with gastroparesisContinuous time measure until capsule elimination
To characterize pressure patterns within the antrum and duodenum in healthy subjects and patients with documented gastroparesisContinuous time measure until capsule elimination
To characterize total GI transit time in healthy subjectsContinuous time measure until capsule elimination

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026